MedTrace Logo

Rosacea Treatment Using Non-thermal (cold) Atmospheric Plasma Device

NCT05592548 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2024-12-04

No results posted yet for this study

Summary

10-13 patients will be enrolled to receive split face treatment: the control side will be treated with metronidazole cream, the intervention side will be treated with a cold atmospheric plasma device

Conditions

  • Rosacea, Papulopustular

Interventions

DEVICE

cold atmospheric plasma

Cold atmospheric plasma will be generated on the skin surface using an electric device

Sponsors & Collaborators

  • The Skin Center Dermatology Group

    lead INDUSTRY

Principal Investigators

  • Peter Friedman, MD PhD · The Skin Center Dermatology Group

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-02
Primary Completion
2024-05-31
Completion
2024-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05592548 on ClinicalTrials.gov